sinc
discoveri
character
earli
viru
attack
immun
system
leav
patient
unabl
fight
opportunist
infect
ebb
flow
effect
treatment
hope
scientist
continu
search
way
erad
human
immunodefici
human
popul
similar
accomplish
case
smallpox
major
effort
nearli
success
come
area
patient
treatment
rather
inhibit
contract
spread
viru
class
treatment
antiretrovir
therapi
art
later
highli
activ
antiretrovir
therapi
haart
mainstay
diseas
control
last
year
notwithstand
increas
life
span
patient
increas
time
fullblown
aid
decreas
contract
opportunist
infect
aidsrel
diseas
ie
nonhodgkin
lymphoma
kaposi
sarcoma
etc
patient
treat
haart
sever
reason
develop
vaccin
still
warrant
five
reason
follow
nearli
twothird
patient
contract
live
underdevelop
countri
afford
expens
haart
art
haart
regimen
complex
disrupt
patient
live
diet
make
longterm
complianc
potenti
side
effect
arthaart
treatment
neg
affect
longterm
health
patient
includ
diabet
cardiovascular
diseas
fractur
develop
haart
drug
resist
presenc
latent
reservoir
harbor
viral
strain
produc
mutat
throughout
durat
infect
host
also
play
role
failur
reason
well
mani
other
underscor
need
prophylact
vaccin
possibl
strongest
argument
develop
prophylact
vaccin
may
need
control
viru
spread
worldwid
everi
day
patient
worldwid
infect
product
vaccin
could
inhibit
infect
reduc
spread
would
aid
reduct
burden
aid
aidsrel
diseas
expens
incur
aid
epidem
hardli
calcul
rang
ten
thousand
dollar
per
patient
haart
regimen
million
dollar
requir
build
orphanag
govern
children
whose
parent
succumb
diseas
unknown
cost
educ
materi
condom
effort
prevent
spread
diseas
public
health
challeng
gone
unnot
address
scientist
ongo
effort
develop
safe
effect
vaccin
prophylact
vaccin
would
offer
steril
immun
patient
prevent
infect
upon
present
viru
prophylact
vaccin
must
also
effect
possibl
portal
entri
especi
occur
vaccin
must
offer
broad
durabl
immun
sever
consortia
work
dilig
produc
vaccin
induc
broadli
reactiv
neutral
antibodi
nab
consortia
includ
major
intern
effort
well
effort
individu
countri
region
institut
includ
limit
intern
aid
vaccin
initi
neutral
antibodi
center
hivaid
vaccin
immunolog
hiv
vaccin
trial
network
us
militari
hiv
research
program
collabor
aid
vaccin
discoveri
vaccin
research
center
nation
institut
allergi
infecti
diseas
nation
institut
health
date
howev
candid
vaccin
induc
broadli
reactiv
absenc
vaccin
prevent
infect
still
mani
benefit
realiz
product
therapeut
vaccin
therapeut
vaccin
would
suprem
valuabl
abl
increas
titer
viru
necessari
infect
increas
time
clinic
manifest
viru
control
viral
load
infect
reduc
secondari
vaccin
could
induc
type
respons
would
invari
decreas
contagi
decreas
need
costli
potenti
danger
arthaart
decreas
number
opportunist
infect
patient
effect
control
normal
patholog
therapeut
vaccin
favor
individu
patient
well
societi
effect
prevent
infect
human
prophylact
vaccin
also
broadli
appeal
potenti
erad
viru
human
host
drive
scientist
continu
find
way
circumv
challeng
present
uniqu
viru
order
induc
product
nab
critic
steril
immun
review
therefor
focu
specif
challeng
present
stride
made
toward
creat
prophylact
vaccin
includ
past
effort
fail
lesson
learn
failur
also
discuss
novel
vaccin
option
promis
trial
current
underway
tradit
prophylact
vaccin
made
expos
part
pathogen
structur
antigen
host
immun
system
elicit
immun
respons
result
product
longterm
memori
lymphocyt
capabl
mount
strong
immun
respons
upon
later
infect
pathogen
premis
upon
manipul
immun
system
base
abil
immun
system
make
longlast
antibodi
conserv
structur
expos
protein
nativ
pathogen
ideal
humor
cellmedi
immun
would
induc
creat
longlast
immun
tradit
attempt
recreat
process
use
live
attenu
simian
immunodefici
virus
effort
vaccin
macaqu
proven
safe
effect
macaqu
subsequ
challeng
howev
incident
studi
effect
liveattenu
contain
delet
nef
gene
long
termin
repeat
proven
pathogen
human
three
six
treat
patient
develop
lateonset
kill
virus
also
test
potenti
vaccin
approach
safeti
concern
halt
use
safeti
concern
includ
incomplet
inactiv
viru
lead
potenti
residu
infect
vaccin
due
ineffect
tradit
vaccin
approach
date
scientist
attempt
use
recombin
protein
stimul
product
nab
attempt
fail
due
inabl
induc
last
broad
rang
nab
would
inhibit
infect
perhap
failur
result
inher
divers
divers
present
major
roadblock
develop
prophylact
vaccin
three
main
group
n
well
recent
discov
group
group
consist
sever
subtyp
clade
variou
clade
display
biolog
differ
respect
diseas
differ
result
inabl
produc
generaliz
vaccin
would
induc
breadth
nab
necessari
counter
infect
wide
rang
clade
may
encount
natur
degre
divers
seen
greater
viru
problem
address
develop
multiclad
multipl
env
andor
subtyp
b
gag
pol
nef
mosaic
vaccin
incorpor
set
immunogen
protein
differ
clade
bival
protein
clade
b
proof
principl
studi
illustr
immunolog
protect
nonhuman
primat
passiv
treat
broadli
reactiv
studi
show
protect
infect
confer
presenc
broadli
reactiv
nab
next
step
toward
product
prophylact
vaccin
would
involv
induct
product
similar
broadli
reactiv
nab
host
immun
system
rate
viru
mutat
due
natur
revers
transcriptas
enzym
respons
transcrib
rna
ensur
nearli
everi
daughter
virion
differ
genom
chang
occur
env
protein
need
antibodi
recognit
inhibit
immun
system
abil
mount
suffici
respons
one
attempt
circumv
problem
induc
product
nab
conserv
region
protein
major
problem
approach
conserv
region
protein
often
shield
exposur
nab
within
envelop
nativ
structur
envelop
protein
reportedli
protein
suscept
shield
immun
system
glycosyl
trimer
heterodim
glycosyl
envelop
protein
allow
carbohydr
masquerad
self
therebi
form
immunolog
silent
face
protect
neighbor
epitop
via
evolv
glycan
shield
addit
coreceptor
bind
site
anoth
conserv
site
present
primari
bind
attempt
creat
antibodi
region
protein
made
rhesu
macaqu
result
indic
vaccin
host
abl
withstand
challeng
attempt
creat
vaccin
focus
overcom
abil
escap
immun
surveil
use
antibodi
abl
neutral
divers
isol
antibodi
includ
recent
identif
antibodi
give
hope
induct
induct
broadli
reactiv
nab
may
provid
basi
prophylact
vaccin
futur
use
anim
model
develop
therapeut
offer
benefit
thorough
test
valid
prior
introduct
vaccin
human
past
vaccin
made
observ
mimick
immun
respons
mount
individu
recov
particular
diseas
date
howev
known
case
individu
recov
infect
howev
data
gather
longterm
nonprogressor
patient
infect
least
year
display
anoth
option
may
critic
develop
prophylact
vaccin
use
relev
anim
model
model
allow
analysi
effect
potenti
vaccin
intact
host
prior
use
human
one
particular
challeng
use
anim
model
develop
prophylact
vaccin
natur
occur
diseas
model
nonhuman
primat
suscept
infect
infect
anim
progress
therefor
import
use
diseas
model
mimic
hivaid
patholog
one
potenti
model
felin
immunodefici
viru
fiv
fiv
discov
known
caus
aidslik
diseas
domest
cat
mimic
hivrel
dementia
vaccin
fiv
approv
fda
fiv
model
potenti
inform
use
suffici
basi
develop
prophylact
vaccin
ideal
anim
model
would
display
patholog
respons
infect
similar
one
occur
human
unfortun
caus
patholog
lead
develop
aid
host
howev
anim
model
develop
use
allow
partial
understand
patholog
natur
immunolog
respons
infect
respons
host
novel
therapeut
one
model
involv
simian
immunodefici
virusmac
sivmac
replic
caus
aidslik
diseas
baboon
cynomolgu
pigtail
macaqu
similar
sivmac
allow
insight
patholog
transmiss
immunolog
respons
infect
host
viru
differ
sivmac
still
great
abl
draw
conclus
regard
potenti
human
respons
prophylact
therefor
broaden
scope
anim
model
usag
chimer
shiv
viru
engin
incorpor
siv
protein
macaqu
infect
shiv
go
develop
aid
time
progress
much
differ
time
progress
aid
human
infect
macaqu
strain
mimic
infect
human
lead
chronic
slow
diseas
progress
rout
dose
requir
infect
viral
tropism
replic
capac
virus
patholog
sivshivinfect
monkey
differ
paramet
distinct
well
character
recent
phase
iib
step
trial
involv
healthi
uninfect
volunt
result
trial
termin
first
schedul
efficaci
assess
due
failur
suppress
viral
load
subsequ
infect
individu
thensuspect
increas
infect
due
interact
immun
system
vaccin
vaccin
recombin
adenoviru
serotyp
viru
incorpor
gag
pol
nef
gene
previous
test
shiv
model
macaqu
result
experi
suggest
result
human
dispar
underscor
need
anim
model
close
reflect
patholog
seen
human
infect
well
identif
immunolog
correl
protect
reflect
control
viral
load
human
subject
therefor
search
appropri
anim
model
appropri
use
current
anim
model
search
prophylact
vaccin
continu
model
deriv
allow
observ
stage
infect
progress
diseas
respons
immun
system
way
compar
process
human
abl
logic
predict
vaccin
candid
move
forward
clinic
trial
sever
attempt
stimul
immun
system
provid
protect
hiv
infect
attempt
far
tabl
hope
creat
prophylact
vaccin
lie
abil
scientif
commun
identifi
induc
broad
neutral
antibodi
respons
would
offer
steril
immun
vaccin
patient
end
sever
novel
approach
studi
vaccin
elicit
robust
immun
respons
long
last
abl
provid
protect
variou
strain
pathogen
plasmid
dna
vaccin
induc
strong
humor
tcell
respons
dnabas
vaccin
use
power
tool
fight
parasit
fungal
bacteri
viral
multipl
advantag
use
plasmid
dna
vaccin
gener
safe
nontox
deliveri
gene
encod
import
immunogen
epitop
dnabas
vaccin
exploit
biosynthet
machineri
host
cell
one
exampl
wherebi
wolff
colleagu
illustr
protein
express
intramuscular
im
inject
plasmid
dna
despit
promis
result
specul
regard
dna
vaccin
strategi
exampl
shown
protein
product
respons
dna
plasmid
contain
hiv
insert
elicit
substanti
cellular
respons
mice
nonhuman
primat
howev
product
poorli
immunogen
human
one
strategi
improv
immun
respons
plasmid
dna
vaccin
strategi
coadministr
dna
plasmid
code
cytokin
eg
infg
second
strategi
util
improv
plasmid
dna
vaccin
administr
plasmid
dna
adjuv
eg
cpg
oligodeoxynucleotid
use
dnadeliveri
system
eg
microparticl
cochleat
linear
polyenimin
third
strategi
improv
vaccin
efficaci
involv
coadministr
plasmid
dna
combin
viral
vector
instanc
research
perform
harari
colleagu
demonstr
vaccin
mean
clade
c
dna
prime
combin
pox
vector
nyvac
boost
induc
reliabl
polyfunct
longlast
antihiv
tcell
respons
human
along
line
work
recent
publish
jaoko
group
demonstr
safeti
immunogen
multiclad
adbas
vaccin
alon
combin
multiclad
dna
vaccin
africa
result
also
demonstr
dna
prime
increas
frequenc
magnitud
cellular
humor
respons
howev
effect
recombin
dosag
immunogen
previous
mention
dnadeliveri
strategi
use
combin
viral
vector
alon
mean
varieti
immun
rout
eg
im
intraven
iv
intraderm
id
intranas
oral
rectal
vagin
major
report
studi
dna
vaccin
administ
im
andor
id
rout
howev
relat
hiv
vaccin
mucos
immun
could
potenti
import
factor
consid
mucos
immun
achiev
optim
oral
rout
administr
topic
mucos
immun
discuss
detail
later
section
within
review
immun
assum
dna
vaccin
immunogen
produc
skelet
muscl
dendrit
cell
macrophag
site
immun
howev
adult
skelet
muscl
involv
high
level
protein
synthesi
compar
liver
therefor
deliveri
dna
cell
capabl
high
protein
synthesi
hepatocyt
epithelia
cell
intestin
salivari
pancrea
may
result
high
level
protein
express
hepatocyt
express
enzym
involv
format
intrachain
interchain
disulfid
bond
requir
proper
fold
assembl
protein
addit
liver
express
glycosyltranferas
essenti
synthesi
n
olink
glycan
side
chain
may
case
cell
signific
point
fact
broadli
crossclad
nab
recogn
glycan
moieti
heavili
glycosyl
envelop
anoth
advantag
protein
express
within
liver
significantli
lower
amount
dna
need
protein
express
particular
antigen
hepatocyt
vs
anoth
cell
type
immun
human
milligram
quantiti
dna
necessari
achiev
adequ
level
immun
method
wherebi
would
reduct
dna
quantiti
need
vaccin
human
would
provid
signific
econom
advantag
base
previous
mention
reason
surpris
liver
exploit
extens
site
gene
deliveri
due
abil
produc
protein
hydrodynam
deliveri
applic
control
hydrodynam
pressur
capillari
enhanc
endotheli
parenchym
cell
permeabl
methodolog
incept
late
investig
intravascular
inject
plasmid
dna
solut
gene
deliveri
whole
hydrodynam
plasmid
dna
deliveri
well
toler
mice
raska
colleagu
demonstr
mice
iv
hydrodynam
vaccin
envelop
dna
inject
result
high
level
express
hiv
antigen
liver
mice
immunolog
data
illustr
hydrodynam
administr
plasmid
dna
superior
vaccin
dna
id
im
intrasplen
rout
result
illustr
boost
hydrodynam
vaccin
yield
level
antibodi
higher
elicit
rout
howev
deliveri
scheme
feasibl
larg
anim
human
altern
receptormedi
dna
bind
hepatocyt
could
viabl
approach
molecul
termin
galactos
residu
coval
link
dna
recogn
hepatocyteexpress
galactosespecif
receptor
altern
would
avoid
deliveri
hepat
system
need
expans
blood
volum
addit
galactoselink
dna
packag
deliveri
vehicl
liposom
choleat
microspher
given
oral
administr
would
absorb
intestin
ultim
deliv
hepat
vein
addit
altern
hydrodynam
deliveri
human
might
possibl
express
hiv
antigen
liver
mean
plasmid
dna
deliveri
via
viral
vector
ad
ad
shown
transduc
liver
effici
vivo
mean
hexon
regard
product
translat
protein
primarili
liver
might
allow
product
heavili
glycosyl
envelop
antigen
thu
product
nab
viral
vector
potent
induc
cellular
humor
respons
viral
vector
express
protein
bacteria
viral
pathogen
vaccin
infecti
diseas
sever
viral
vaccin
vector
use
success
model
vaccin
vector
includ
alphavirus
human
rhinovirus
hrv
ad
picornavirus
poxvirus
measl
virus
influenza
vaccinia
vector
respect
disadvantag
advantag
respect
vaccin
develop
advantag
vector
includ
abil
natur
infect
wide
varieti
cell
type
tissu
respect
vector
set
disadvantag
instanc
one
disadvantag
use
polioviru
hrv
vaccin
vector
insert
size
limit
restrict
vector
compar
larg
insert
size
kb
accommod
ad
vector
common
disadvantag
major
viral
vaccin
vector
reduc
vaccin
efficaci
due
vector
preexist
immun
pei
variou
strategi
employ
circumv
problem
associ
vector
pei
specif
relat
ad
vector
pei
tremend
problem
identifi
serotyp
ad
vector
human
serotyp
extens
use
gene
therapi
protocol
use
vaccin
protocol
recent
step
studi
relat
pei
vector
may
found
american
popul
popul
countri
ad
pei
limit
effect
adbas
circumv
pei
research
employ
use
vector
use
altern
use
nonhuman
chimpanze
ad
chimpanze
ad
viru
demonstr
significantli
neutral
human
sera
give
chimpanze
ad
advantag
human
vaccin
strategi
use
reduc
immun
respons
ad
vector
use
helperdepend
ad
hdad
use
ad
deliveri
combin
biochem
modif
use
vector
deliveri
mean
cell
respect
hdad
vector
produc
increas
safeti
clone
capac
firstgener
ad
vector
hdad
lack
ad
gene
contain
packag
signal
end
termin
repeat
vector
design
avoid
cellular
immun
diminish
liver
toxic
thu
promot
longterm
transgen
reduc
immun
respons
hdad
allow
transgen
express
mice
baboon
longterm
transgen
express
could
help
antigen
product
hiv
vaccin
thu
produc
opportun
increas
protect
hiv
reduc
frequenc
vaccin
although
nab
may
reduc
immunogen
vector
anim
model
system
effect
immun
subject
previou
exposur
still
larg
unknown
previous
mention
step
trial
test
merck
recombin
vaccin
encod
gag
pol
gene
fail
yield
protect
either
lower
viral
load
decreas
acquisit
analysi
data
studi
arous
specul
subject
preexist
nab
wildtyp
infect
increas
risk
hiv
infect
vaccin
one
recent
studi
shown
caus
role
cell
increas
suscept
merck
regard
multipl
studi
ongo
elucid
concret
find
respect
role
pei
increas
activ
cell
mucos
recent
report
cheng
colleagu
attempt
character
specif
nab
immun
subject
determin
impact
ad
exposur
immun
respons
elicit
vaccin
cheng
colleagu
report
nab
direct
toward
differ
compon
ad
virion
depend
whether
infect
natur
adbas
hiv
vaccin
trial
exampl
ad
nab
gener
natur
infect
direct
primarili
fiber
compon
vector
exposur
elicit
respons
primarili
capsid
protein
fiber
nab
elicit
natur
infect
significantli
reduc
cell
respons
hiv
gag
vaccin
report
conclud
nab
differ
base
rout
exposur
previou
exposur
compromis
vaccineinduc
immun
weak
immunogen
result
tremend
impact
vaccin
trial
design
next
gener
viral
vaccin
vector
viral
vector
ad
influenza
polio
use
vaccin
vector
mani
reason
one
import
advantag
vector
make
attract
provid
mucos
immun
easili
infect
mucos
surfac
well
act
induc
cytokin
chemokin
product
mucos
entri
site
ad
influenza
polio
also
advantag
abl
deliv
oral
without
use
needl
import
fact
develop
countri
needl
cost
prohibit
vaccin
administr
relat
hiv
vaccin
develop
mucos
immun
debat
factor
consid
decid
upon
vaccin
agent
import
consid
ultim
goal
induc
system
immun
mucos
immun
worth
care
believ
infect
occur
heterosexu
viral
transmiss
rest
occur
homosexu
perinat
although
biolog
sexual
transmiss
poorli
understood
clear
essenti
first
step
infect
pathway
transfer
infecti
viru
hivinfect
cell
mucos
surfac
hiv
enter
new
host
hiv
hivinfect
cell
soon
encount
suscept
host
target
cell
mucos
point
entri
viru
replic
invad
local
lymphat
tissu
initi
system
hiv
infect
basi
strong
immun
requir
provid
protect
immunolog
barrier
common
point
entri
mucos
surfac
reproduct
tract
due
compartment
secretori
system
immun
system
parenter
administ
antigen
consist
stimul
mucos
therefor
import
consid
vaccin
regim
induc
mucos
immun
sinc
memori
cell
primari
target
hiv
infect
gut
mucosa
rapid
deplet
subset
occur
earli
sever
studi
investig
role
hiv
mucos
immun
previou
studi
demonstr
import
mucos
sivhiv
vaccin
produc
strong
mucos
antibodi
respons
capabl
block
escap
viru
intestin
mucosa
system
lymphoid
howev
instanc
necess
exclus
mucos
hiv
immun
debat
base
promis
result
found
heterolog
primeboost
regimen
use
siv
modifi
vaccinia
viru
ankara
express
siv
transcript
control
vaccinia
viru
earlyl
promot
case
either
id
im
dnamva
vaccin
abl
provid
protect
intrarect
challeng
along
line
recent
promis
result
found
hessel
colleagu
hessel
colleagu
demonstr
iv
administr
monoclon
antibodi
six
monkey
follow
shivbal
challeng
five
six
monkey
either
group
show
complet
protect
steril
immun
low
level
viral
replic
could
rule
six
monkey
either
replic
ad
yield
robust
immun
respons
mucos
site
partli
ad
known
infect
replic
epitheli
variou
strategi
use
achiev
mucos
immun
via
oral
rout
one
strategi
embodi
develop
replicationdefect
recombin
ad
serotyp
serotyp
vector
current
use
natur
tropism
gut
caus
patholog
diseas
outsid
gastrointestin
vector
like
preferenti
tropism
gut
appear
resist
acid
capsid
configur
long
short
fiber
allow
viru
preferenti
infect
previous
mention
viral
vector
potent
induc
cellular
humor
respons
note
viral
vector
practic
use
human
applic
progress
treat
varieti
diseas
context
cancer
infecti
tradit
viral
vector
immun
embodi
concept
vector
use
host
cell
machineri
express
antigen
encod
transgen
within
viral
vector
cellular
humor
immun
respons
gener
antigen
last
year
sever
viral
vector
deriv
express
antigen
vaccin
purpos
research
taken
altern
approach
convent
transgen
express
antigen
mean
viral
vector
altern
approach
embodi
capsid
incorpor
antigen
innov
paradigm
base
upon
vector
present
antigen
compon
capsid
rather
encod
transgen
incorpor
immunogen
peptid
vector
capsid
offer
potenti
advantag
regard
process
capsidincorpor
antigen
via
exogen
pathway
result
strong
humor
respons
similar
respons
provok
nativ
ad
capsid
protein
arrang
potenti
hiv
peptid
antigen
accru
potent
immunostimulatori
effect
nativ
ad
vector
capsid
protein
effect
perform
adjuv
function
basi
immun
respons
direct
vector
capsid
protein
repetit
vector
administr
achiev
booster
effect
incorpor
importantli
relat
hiv
infect
strategi
yield
potenti
gener
antibodi
hiv
protein
recent
crystallograph
cryoelectron
tomographi
molecular
model
studi
provid
valuabl
insight
molecular
surfac
recogn
antibodi
well
assist
rational
vaccin
design
structur
technolog
also
potenti
improv
abil
scientist
advanc
antigen
capsidincorpor
strategi
antigen
capsid
incorpor
effect
provid
way
forward
respect
induc
steril
antigen
capsidincorpor
strategi
use
adbas
vaccin
context
mani
one
first
exampl
antigen
capsidincorpor
strategi
use
research
perform
crompton
crompton
colleagu
insert
eightamino
acid
sequenc
capsid
protein
polioviru
type
two
region
serotyp
hexon
one
chimer
vector
produc
grew
well
tissu
cultur
addit
antiserum
rais
ad
polio
insert
specif
recogn
capsid
polio
type
relat
serotyp
wu
group
demonstr
epitop
could
incorpor
ad
hexon
hypervari
region
hvr
reclassifi
without
perturb
viral
viabil
major
biolog
characterist
replic
thermost
nativ
infect
studi
wu
colleagu
demonstr
appear
surfac
expos
respect
peptid
incorpor
within
hexon
appear
promis
local
peptideantigen
incorpor
base
xray
peptid
analys
along
molecular
laboratori
other
focus
incorpor
singlesit
incorpor
fiber
pix
howev
recogn
abil
place
antigen
within
multipl
site
ad
capsid
protein
would
hold
import
potenti
present
multipl
epitopesantigen
sever
copi
epitop
within
singl
ad
vectorbas
vaccin
effort
creat
multival
hiv
vaccin
vector
studi
explor
use
hope
creat
vector
contain
hiv
antigen
epitop
local
compar
flexibl
capac
genet
incorpor
ident
epitop
increment
increas
size
within
hexon
incorpor
ident
epitop
rang
amino
acid
within
hexon
region
viabl
virus
produc
incorpor
amino
acid
plu
acid
linker
addit
viabl
virus
produc
incorpor
amino
acid
plu
acid
linker
respect
ident
antigen
incorpor
permiss
allow
epitop
incorpor
amino
acid
total
model
antigen
surfac
expos
via
elisa
analysi
vivo
immun
vector
illustr
antigenspecif
immun
along
line
abe
colleagu
evalu
abil
vector
express
hiv
transgen
induc
antigenspecif
immun
respons
preimmun
condit
overcom
limit
gener
experienc
result
pei
construct
vector
modif
studi
character
variou
immunolog
paramet
gener
vector
vector
neutral
acquisit
adapt
immun
respons
comparison
protect
immun
first
order
evalu
util
modifi
ad
vector
measur
neutral
activ
sera
modifi
ad
vector
administ
adluc
luciferas
protein
express
transgen
ad
region
adhisluc
epitop
present
region
luciferas
protein
express
transgen
adendaaaluc
vector
contain
three
amino
acid
mutat
express
luciferas
protein
mice
im
administr
vector
neutral
activ
observ
week
hexonmodifi
vector
adhisluc
gener
lowest
neutral
activ
significantli
lower
gener
adluc
week
adendaaaluc
vector
week
individu
neutral
activ
adhisluc
immun
significantli
lower
adluc
immun
addit
studi
perform
abe
colleagu
support
concept
modifi
hexon
thwart
nab
promot
cellular
immun
respons
studi
perform
research
group
indic
chang
immunogen
epitop
necessari
avoid
neutral
preexist
nab
recent
publish
work
exploit
antigen
capsidincorpor
strategi
hiv
vaccin
novel
vector
construct
hope
move
toward
goal
creat
vector
provid
cellular
humor
hiv
immun
studi
first
kind
genet
incorpor
hiv
antigen
within
hexon
alon
combin
genom
incorpor
gag
transgen
gag
studi
success
incorpor
acid
epitop
within
region
select
incorpor
membran
proxim
ectodomain
region
mper
deriv
glycoprotein
rational
choos
portion
mper
eknekelleldkwaslwnwfditn
deriv
base
fact
envelop
protein
ectodomain
target
three
broadli
neutral
mper
incorpor
combin
transgen
express
observ
growth
kinet
thermost
chang
similar
capsidincorpor
vector
gener
indic
incorpor
mper
epitop
within
dramat
detriment
virolog
addit
demonstr
mper
epitop
surfac
expos
within
importantli
observ
humor
antihiv
respons
mice
vaccin
hexonmodifi
vector
mpermodifi
vector
allow
boost
compar
adcmvgag
possibl
gag
ad
elicit
less
immun
respons
possibl
mper
epitop
reduc
immunogen
vector
find
noteworthi
fulli
explor
antigen
capsidincorpor
vector
current
analyz
cryoelectron
microscop
analysi
determin
critic
correl
relat
antigen
placementconfigur
immun
respons
addit
respect
vaccin
antigen
capsidincorpor
strategi
evalu
within
context
hrv
research
group
construct
human
rhinoviru
chimera
effort
stimul
immun
effort
develop
vaccin
research
within
group
gener
combinatori
librari
hrv
capsidincorpor
epitop
result
indic
success
elicit
antibodi
whose
activ
mimic
nab
commerci
clinic
ad
develop
vaccin
progress
preferenti
vector
system
hrv
flexibl
ad
gener
exce
current
rhinoviru
system
exampl
hrv
rel
small
rna
viru
hrv
platform
display
array
limit
copi
singl
contrast
ad
vector
platform
allow
incorpor
mper
epitop
three
structur
distinct
local
includ
protein
ix
unpublish
data
comparison
ad
mper
antigen
capsidincorpor
display
platform
could
present
array
epitop
copi
within
ad
hexon
epitop
copi
within
pix
multival
ad
vector
gener
epitop
within
hexon
pix
local
would
repres
hiv
epitop
within
one
ad
vector
anoth
signific
differ
ad
hrv
platform
number
local
success
use
heterolog
epitop
insert
final
contrast
rhinoviru
lack
capac
ad
platform
suffici
code
capac
allow
transgen
express
combin
present
differ
antigen
viral
capsid
surfac
latter
find
import
provid
basi
construct
vector
provid
cellular
humor
immun
vector
provid
cellular
humor
immun
may
way
forward
respect
prophylact
hiv
vaccin
develop
recent
encourag
develop
regard
hiv
vaccin
thailand
substanti
increas
preval
infect
first
observ
group
consist
intravenousdrug
user
commerci
sex
worker
infect
group
expand
gener
mid
overal
seropreval
reach
peak
among
member
royal
thai
armi
among
peopl
northern
thai
ministri
public
health
act
start
effect
hivprevent
campaign
effort
number
new
infect
per
year
decreas
estim
although
decreas
promis
still
desir
prevent
hiv
infect
achiev
goal
hiv
phase
iii
studi
begun
thai
phase
iii
hiv
vaccin
studi
also
known
open
fall
placebocontrol
trial
test
safeti
effect
primeboost
regimen
two
vaccin
alvachiv
vaccin
prime
modifi
canarypox
vaccin
aidsvax
vaccin
booster
gp
vaccin
vaccin
base
subtyp
e
b
strain
commonli
circul
thailand
subtyp
b
strain
commonli
found
strain
unit
state
trial
conduct
chonburi
rayong
provinc
thailand
enrol
women
men
age
year
variou
level
risk
hiv
infect
studi
particip
receiv
placebo
alvac
hiv
vaccin
enrol
month
placebo
aidsvax
vaccin
given
particip
month
particip
test
infect
everi
month
year
clinic
visit
studi
particip
counsel
prevent
infect
result
show
placebo
recipi
becam
infect
compar
particip
receiv
vaccin
level
effect
prevent
infect
found
statist
signific
vaccin
strategi
effect
howev
amount
viru
blood
volunt
acquir
infect
studi
base
final
analysi
studi
surgeon
gener
us
armi
trial
sponsor
announc
primeboost
investig
vaccin
regimen
safe
effect
prevent
infect
respect
vaccin
provid
steril
hiv
immun
best
result
human
date
howev
modest
protect
effect
appear
limit
lowrisk
individu
data
suggest
effect
confin
first
year
follow
administr
vaccin
effort
must
continu
focu
evalu
immun
respons
induc
vaccin
establish
potenti
correl
protect
last
three
decad
world
face
emerg
subsequ
epidem
hivaid
much
progress
respect
diagnosi
prevent
treatment
front
sever
signific
advanc
respect
drug
develop
ie
arthaart
howev
desper
need
effect
safe
vaccin
tremend
difficulti
regard
develop
vaccin
provid
steril
immun
case
due
factor
mention
review
hiv
divers
immun
evas
lack
appropri
anim
model
due
obstacl
mani
research
assum
control
viremia
vaccin
would
realist
goal
develop
steril
immun
road
safe
effect
vaccin
receiv
seriou
setback
fall
prematur
termin
vaccin
step
trial
due
lack
efficaci
earli
specul
vaccin
might
increas
risk
hiv
infect
popul
vaccine
late
promis
result
came
thailand
respons
effort
creat
safe
effect
vaccin
communitybas
random
multicent
doubleblind
placebocontrol
efficaci
trial
use
primeboost
combin
show
effect
prevent
infect
result
lend
promis
hope
produc
vaccin
vector
yield
steril
immun
futur
research
scientist
must
work
togeth
increas
vaccin
effect
beyond
realiz
goal
may
accomplish
techniqu
mention
review
acquisit
hiv
mucos
immun
develop
effect
primeboost
strategi
develop
better
anim
model
better
molecular
antigen
model
present
avoid
pei
mean
use
novel
vector
serotyp
combin
pegyl
andor
induct
nab
mean
capsid
incorpor
hiv
antigen
within
viral
vector
consider
scientist
clinician
must
consid
respect
develop
effect
safe
vaccin
scientist
clinician
must
also
consid
one
vector
scheme
may
suffici
respect
provid
effect
immun
combin
abovement
potenti
strategi
may
offer
promis
method
produc
effect
prophylact
vaccin
